According to the latest data reported on its website, the
Common Drug Review (CDR) has continued its historic pattern by
recommending against the listing of approximately 50% of the
new drugs it reviewed in 2007.
CDR issued a total of 29 recommendations last year; 27 were
recommendations based on submissions by manufacturers and 2
were recommendations resulting from requests for advice by
participating public drug plans. Only one drug received a full
listing recommendation. In 14 cases, CDR recommended partial
listings, subject to specific criteria or conditions, or
listing in a similar manner to drugs in the same therapeutic
class by that drug plan. In the remaining 14 cases, CDR
recommended that the drug not be listed at all. These trends
are similar to the pattern of CDR recommendations in previous
The CDR also reports that a total of 19 drugs are currently
In comparing the CDR recommendations with reviews by the
Patented Medicine Prices Review Board (PMPRB) based on
information published on the PMPRB's website, for the
29 drugs with CDR recommendations in 2007, 15 are reported by
the PMPRB as being priced within its excessive price
guidelines, eight are under review or under investigation and
six have not been reported by the PMPRB to date.
The CDR is a federal/provincial/territorial (F/P/T) process
to review the clinical efficacy and cost effectiveness of new
drugs for purposes of recommending coverage under public drug
programs. The PMPRB is a federal agency responsible for
ensuring that the prices of patented medicines are not
The Canadian Agency for Drugs and Technologies in Health
(CADTH) reports on the status of CDR submissions, maintains a
searchable database, and publishes summary reports on
recommendations. For access to these documents, please
The content of this article is intended to provide a
general guide to the subject matter. Specialist advice should
be sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.
From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.
Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.
Effective September 1, 2016, the Disposition of Surplus Real Property Regulation to the Ontario Education Act was amended with the intention to reduce barriers to the formation of health and community hubs in Ontario.
This appeal relates to two generic drug submissions for two different products: exemestane and infliximab. Both submissions cross-referenced the submission of another generic company that had received a Notice of Compliance.
Two recent decisions from the Supreme Court of Canada directly affect Quebec's farm businesses by confirming La Financière Agricole du Québec's discretion in the administration of the farm income stabilization program...
On October 6, 2016, the Ontario Legislature reintroduced the Patients First Act, 2016 as Bill 41. Bill 41 is very similar to its predecessor, Bill 210, which was introduced in June 2016, but makes some important changes to the previous bill.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).